Project Description

The project involves the strategic consolidation, digital transformation, and expansion of Francesco Saba Dental Clinics (Ostia 1 SRL) into Saba 2.0, a scalable, digital-first healthcare group in the Lazio region of Italy. Building on a legacy of two decades and 16 high-performing clinics, this venture introduces a multi-year strategy to integrate advanced digital tools, expand the clinical footprint, and diversify into adjacent medical services like dermatology and physiotherapy. The project aims to evolve a local leader into a global innovator by leveraging a state-of-the-art centralized laboratory and a standardized operating model.

Project Objectives

• Network Expansion: To grow from 16 clinics to over 20 clinics worldwide by 2028, utilizing a proven scalability model that has already seen the group expand from 12 to 16 clinics between 2022 and 2024.

• Dual Revenue Model: To combine two engines of growth: recurring patient revenues from the clinic network and wholesale-scale production income from B2B laboratory contracts.

• Market Positioning: To maintain high clinical excellence with patient retention rates of 81% after two years, while positioning the brand as a "family of professionals" committed to long-term care.

• Operational Excellence: To implement a fully digital infrastructure featuring AI-powered diagnostics, telemedicine, and standardized HR and finance workflows to ensure consistent quality across all locations.

Services Provided

• Clinical Dentistry: Comprehensive care including preventive hygiene, orthodontics (traditional and invisible), implantology, and aesthetic dentistry.

• Centralized Laboratory: A high-tech hub providing CAD/CAM milling, 3D printing, and digital workflows for both internal clinics and external B2B partners.

• Service Diversification: Introduction of multi-purpose ambulatories offering dermatology and physiotherapy treatments to increase revenue per clinic.

• Education & Training: Operation of the "Saba Academy" to provide internal training, mentorship programs, and continuous professional development for staff.

Project Timeline

Phase 1: Foundation & Optimization (2025 Q3 – 2026 Q1) Formalization of leadership roles and centralization of recruitment. Launch of integrated digital platforms for HR and Finance. Optimization of clinic layouts to introduce new medical services, targeting an 8% revenue increase per clinic.

Phase 2: Expansion & Innovation (2026 Q1 – 2026 Q4) Scaling of the dental laboratory with external financing to expand B2B services. Standardization of all operational procedures and creation of a dedicated R&D role to scout new locations and franchise opportunities.

Stabilization (2027 – 2030) Full operational maturity with a target of 32 clinics by 2030. Projected turnover is expected to grow from €10 Million in 2026 to €18 Million in 2030, with EBITDA margins stabilizing between 25-30%.

Budget Estimate

The project requires a financing requirement of USD 20 Million to fuel expansion and technological upgrades.

• Turnover Projection (2026): €10 Million.

• EBITDA Target: >25% margin.

• Allocation: Funds are structured to support clinic acquisition, laboratory technology upgrades (CAD/CAM), and digital transformation.

Key Project Team

• Medical Strategist & Founder (Dr. Francesco Saba): Visionary clinician with 20 years of expertise, shifting focus from direct clinical work to mentorship and laboratory innovation.

• Executive Director & Investor (Pascal Scarfò): Expert in financial structuring and governance, responsible for leading the digital transformation and international expansion.

• Digital Transformation Lead (Chiara D'Emilia): Responsible for harmonizing HR, finance, and patient systems across the network.

• HR Manager (Federica Zoccoli): Oversees workforce growth, recruitment drives, and the Saba Academy.

• Lab Director (Agostino Cernili): Manages the expansion of the laboratory's B2B services and technological integration.

Additional Features

• Investor Return Strategy: Offers a 6% preferred return (paid annually in Year 1, quarterly thereafter) plus a 20% profit share of annual EBITDA.

• Security & Exit: Secured by a share pledge over company shares, with a defined exit strategy via sale or mandatory redemption within 60 months.

• Technology Edge: Utilization of advanced diagnostics including intraoral cameras, 3D dental scans, and digital impressions to reduce costs and improve patient outcomes.

• Resilient Business Model: A defensive investment mix of stable healthcare demand and scalable international growth.